Allogeneic double‐negative T cell therapy for relapsed <scp>acute myeloid leukemia</scp> patients post <scp>allogeneic hematopoietic stem cell transplantation</scp>: A first‐in‐human phase I studyBaolin Tang, Xiaoyu Zhu, Wen Yao et al.|American Journal of Hematology|2022Cited by 26
A preclinical study of allogeneic <scp>CD19</scp> chimeric antigen receptor double‐negative T cells as an off‐the‐shelf immunotherapy drug against B‐cell malignanciesDan Wang, Liming Yang, Liuyang Wang et al.|Clinical & Translational Immunology|2024Cited by 2